Aspergillosis and mucormycosis - systemic mycoses of importance in COVID-19: Review article
DOI:
https://doi.org/10.33448/rsd-v10i7.17101Keywords:
Aspergillosis; Mucormycosis; Coronavirus infections.Abstract
Introduction: Invasive aspergillosis and mucormycosis are alarming infections in solid organ and hematopoietic cell transplant recipients. In the context of the pandemic caused by SARS-CoV2, cases of these conditions associated with increased hospital stay and dismal outcomes have been evidenced. Invasive fungal infections represent relevant entities in the care of critically ill patients affected by this coronavirus. Objective: to evaluate the importance of aspergillosis and mucormycosis in patients affected by COVID-19. Methodology: This is a narrative review study that is configured as a qualitative and exploratory study. To this end, an analysis of articles published in the PUBMED database was carried out, as well as of printed books on the subject. The terms used for the research were: “Aspergillosys”, “Mucormycosis” and “Coronavirus Infections”. Results: Invasive aspergillosis and mucormycosis are complications related to increased mortality in patients with COVID-19. Conclusion: Invasive aspergillosis and mucormycosis are entities with high mortality, representing a side effect that should be addressed early in cases of deterioration in the clinical condition of an individual undergoing treatment with corticosteroids and immunosuppressants with COVID-19.
References
Ahmadikia, K., Jamal Hashemi, S., Khodavaisy, S., Ibrahim Getso, M., Alijani, N., Badali, H., Mirhendi, H., Salehi, M., Tabari, A., Mohammadi Ardehali, M., Kord, M., Roilides, E., & Rezaie, S. (2021). The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses, 00, 1–11. https://doi.org/10.1111/myc.13256
Bartoletti, M., Pascale, R., Cricca, M., Rinaldi, M., Maccaro, A., Bussini, L., Fornaro, G., Tonetti, T., Pizzilli, G., Francalanci, E., Giuntoli, L., Rubin, A., Moroni, A., Ambretti, S., Trapani, F., Vatamanu, O., Ranieri, V. M., Castelli, A., Baiocchi, M., … … PREDICO study group. (2020). Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, ciaa1065. https://doi.org/10.1093/cid/ciaa1065
Berto, C., & Dalzochio, T. (2021). Nephrotoxicity and fungal resistance associated with Amphotericin B. Saúde e Meio Ambiente: Revista Interdisciplinar, 10, 45–62. https://doi.org/10.24302/sma.v10.3136
Bongomin, F., Gago, S., Oladele, R. O., & Denning, D. W. (2017). Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. Journal of Fungi (Basel, Switzerland), 3(4), 57. https://doi.org/10.3390/jof3040057
CDC. (n.d.). Symptoms of Mucormycosis | Mucormycosis | CDC. Centers for Disease Control and Prevention. Retrieved June 3, 2021, from https://www.cdc.gov/fungal/diseases/mucormycosis/symptoms.html
Corroza, M., Naranjo, L., Romero, A., Schmauck, T., & Veja, E. (2020). COVID-19 Aspectos biológicos, clínicos y sociológicos: uma revisón. Nulliusin Verba Site, 1–25.
Imhof, A., Balajee, S. A., Fredricks, D. N., Englund, J. A., & Marr, K. A. (2004). Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 39(5), 743–746. https://doi.org/10.1086/423274
Jeffery-Smith, A., Taori, S. K., Schelenz, S., Jeffery, K., Johnson, E. M., Borman, A., Candida auris Incident Management Team, Manuel, R., & Brown, C. S. (2017). Candida auris: a Review of the Literature. Clin Microbiol Rev, 31(1), e00029-17. https://doi.org/10.1128/CMR.00029-17
Lai, C. C., & Yu, W. L. (2021). COVID-19 associated with pulmonary aspergillosis: A literature review. Journal of Microbiology, Immunology and Infection, 54(1), 46–53. https://doi.org/10.1016/j.jmii.2020.09.004
Marinho, V. R. D., Villarim, C. V. O., Silva, L. C. C. e, Silva, A. L. C. e, Araújo-Neto, I., Caldas, D. M. D. R., Rêgo, A. C. M., & Araújo-Filho, I. (2021). Use of heparin in patients with severe COVID-19: What is the evidence? Research, Society and Development, 10(6), e28910615820. https://doi.org/10.33448/rsd-v10i6.15820
Marr, K. A., Schlamm, H. T., Herbrecht, R., Rottinghaus, S. T., Bow, E. J., Cornely, O. A., Heinz, W. J., Jagannatha, S., Koh, L. P., Kontoyiannis, D. P., Lee, D. G., Nucci, M., Pappas, P. G., Slavin, M. A., Queiroz-Telles, F., Selleslag, D., Walsh, T. J., Wingard, J. R., & Maertens, J. A. (2015). Combination antifungal therapy for invasive aspergillosis a randomized trial. Annals of Internal Medicine, 162(2), 81–89. https://doi.org/10.7326/M13-2508
Marsh, B. M., Rajasingham, R., Tawfic, S. H., & Borofsky, M. S. (2018). Successful Conservative Management of Bilateral Renal Mucormycosis. Urology, 120, 2–5. https://doi.org/10.1016/j.urology.2018.03.010
Martín-Rabadán, P., Gijón, P., Fernández, R. A., Ballesteros, M., Anguita, J., & Bouza, E. (2012). False-positive Aspergillus Antigenemia Due to Blood Product Conditioning Fluids. Clinical Infectious Diseases, 55(4), e22–e27. https://doi.org/10.1093/cid/cis493
Mekonnen, Z. K., Ashraf, D. C., Jankowski, T., Grob, S. R., Vagefi, M. R., Kersten, R. C., Simko, J. P., & Winn, B. J. (2021). Acute Invasive Rhino-Orbital Mucormycosis in a Patient with COVID-19-Associated Acute Respiratory Distress Syndrome. Ophthalmic Plastic and Reconstructive Surgery, 37(2), E80. https://doi.org/10.1097/IOP.0000000000001889
Neufeld, P. M. (2020). A COVID-19 e o diagnóstico da aspergilose pulmonar invasiva. Rev. Bras. An. Clin., 52(2), 173–185. https://doi.org/10.21877/2448-3877.20200019
Permpalung, N., Chiang, T. P., Massie, A. B., Zhang, S. X., Avery, R. K., Nematollahi, S., Ostrander, D., Segev, D. L., & Marr, K. A. (2021). COVID-19 Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, ciab223. https://doi.org/10.1093/cid/ciab223
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., Kontoyiannis, D. P., & Walsh, T. J. (2005). Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 41(5), 634–653. https://doi.org/10.1086/432579
Roilides, E., Zaoutis, T. E., & Walsh, T. J. (2009). Invasive zygomycosis in neonates and children. Clinical Microbiology and Infection, 15(SUPPL. 5), 50–54. https://doi.org/10.1111/j.1469-0691.2009.02981.x
Tavares, W., & Marinho, L. A. C. (2015). Rotinas de diagnósticos e tratamento das doenças infecciosas e parasitárias.
Wang, C., Horby, P. W., Hayden, F. G., & Gao, G. F. (2020). A novel coronavirus outbreak of global health concern. The Lancet, 395(10223), 470–473. https://doi.org/10.1016/S0140-6736(20)30185-9
Wang, H., Ding, Y., Li, X., Yang, L., Zhang, W., & Kang, W. (2003). Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. The New England Journal of Medicine, 349(5), 507–508. https://doi.org/10.1056/NEJM200307313490519
Zuo, T., Zhan, H., Zhang, F., Liu, Q., Tso, E. Y. K., Lui, G. C. Y., Chen, N., Li, A., Lu, W., Chan, F. K. L., Chan, P. K. S., & Ng, S. C. (2020). Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge. Gastroenterology, 159(4), 1302-1310.e.5. https://doi.org/10.1053/j.gastro.2020.06.048
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Ramiro Moreira Tavares; Cicero Emanoel Alves Leite; Ravel Moreira Tavares; Patrícia Lopes Oliveira; Ocilma Barros de Quental
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
